

12 April 2017

Investment Facility Terminated

Anteo Diagnostics Limited (ASX:ADO) (“**Anteo**” or the “**Company**”) wishes to advise that following the Company’s securing additional working capital from shareholders, the CEO and the majority of Board Members and an extension of the payment date from the Vendors, the Company’s investment facility with Bergen Global Opportunity Fund, LP (“**Bergen**”) announced to the market on 3 March 2016 has been terminated.

Anteo’s Non-Executive Chairman, Dr John Hurrell, said “Anteo has been advancing a number of alternatives to meet its earn-out and Vendor finance liabilities associated with the acquisition of DIAsource ImmunoAssays SA and to progress the building of the Anteo business. In the meantime, the funds raised from Bergen provided the Company with working capital to meet its obligation”.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com